Floatz logo

Linsitinib

Recurrent Prostate Cancer

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

514 Active assets in the Recurrent Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
VIPIVOTIDE TETRAXETAN
Novartis Pharmaceuticals
Phase 4BB

View all 50 →

Same molecule, other indications

Linsitinib is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
hormone-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →